Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
8.56M
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
85.4M
-
Shares change
-
-1.74M
-
Total reported value, excl. options
-
$126M
-
Value change
-
-$2.7M
-
Put/Call ratio
-
0.06
-
Number of buys
-
50
-
Number of sells
-
-52
-
Price
-
$1.48
Significant Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q3 2023
132 filings reported holding ATRA - Atara Biotherapeutics, Inc. - Common Stock as of Q3 2023.
Atara Biotherapeutics, Inc. - Common Stock (ATRA) has 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 85.4M shares
.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (9.77M shares), JPMORGAN CHASE & CO (8.67M shares), WASATCH ADVISORS LP (8.4M shares), BlackRock Inc. (7.7M shares), VANGUARD GROUP INC (6.61M shares), MAVERICK CAPITAL LTD (6.29M shares), Redmile Group, LLC (6.28M shares), GOLDMAN SACHS GROUP INC (4.12M shares), D. E. Shaw & Co., Inc. (3.91M shares), and STATE STREET CORP (2.52M shares).
This table shows the top 106 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.